Hot Pursuit     04-Aug-21
Alkem labs launches Ibuprofen, Famotidine tablets in US
Alkem Laboratories announced the launch of Ibuprofen and Famotidine tablets (800 mg/26.6 mg) in the United States, following an approval from the United States Food and Drug Administration (US FDA).

Ibuprofen and Famotidine tablets is AB-rated generic therapeutic equivalent version of Horizon Medicines LLC's Duexis tablets, 800 mg/26.6 mg.

This combination medication is used to relieve pain from rheumatoid arthritis and osteoarthritis while decreasing the risk of developing an ulcer from Ibuprofen use.

"This is the first generic approval of Duexis tablets, 800 mg/26.6 mg by the US FDA. The launch is a subject of ongoing litigation,” the company said in a statement.

The announcement was made before market hours today, 4 August 2021.

Alkem Laboratories is a pharmaceutical company with global operations. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and International markets.

The company's board will meet on 6 August 2021 to consider and approve financial results for the quarter ended on 30 June 2021.

The scrip is currently up 0.30% at Rs 3,520.15 on the BSE. In the past three months, the stock has gained 26.10% while the benchmark Sensex has added 12.28% during the same period.

Previous News
  Alkem Laboratories fixes record date for interim dividend
 ( Market Beat - Reports 01-Feb-24   19:30 )
  Alkem Lab Mandva facility gets 3 USFDA observations
 ( Hot Pursuit - 02-Dec-23   11:08 )
  Alkem Labs appoints Dr. Vikas Gupta as CEO
 ( Hot Pursuit - 15-Sep-23   12:45 )
  Alkem Lab Q1 PAT more than doubles to Rs 287 cr
 ( Hot Pursuit - 10-Aug-23   15:30 )
  Alkem Laboratories to convene AGM
 ( Corporate News - 28-Jun-24   19:25 )
  Alkem Lab gains as Indore facility gets EIR from USFDA
 ( Hot Pursuit - 24-Feb-23   09:46 )
  Alkem Laboratories Ltd soars 1.6%, rises for third straight session
 ( Hot Pursuit - 17-May-24   13:05 )
  Alkem Laboratories consolidated net profit declines 39.21% in the September 2022 quarter
 ( Results - Announcements 11-Nov-22   14:37 )
  Board of Alkem Laboratories recommends Final Dividend
 ( Corporate News - 20-May-23   10:27 )
  Alkem Laboratories Ltd soars 2.64%, Gains for third straight session
 ( Hot Pursuit - 08-Feb-23   13:05 )
  Alkem Laboratories Ltd soars 0.5%, rises for fifth straight session
 ( Hot Pursuit - 19-Jul-22   13:00 )
Other Stories
  PEL board OKs ad hoc appointments post Rupen Patel's passing
  06-Jul-24   16:41
  Info Edge Q1 FY25 billings climb 11% YoY
  06-Jul-24   15:50
  IndusInd Bank advances climb 16% YoY in Q1 FY25
  06-Jul-24   15:18
  Adani Wilmar reports 13% volume growth in Q1 FY25
  06-Jul-24   14:44
  Tata Motors JLR wholesale rises 5% YoY in Q1
  06-Jul-24   13:01
  Marico's domestic biz sees modest volume growth in Q1
  06-Jul-24   12:25
  Titan revenue rises 9% YoY, adds 61 stores in Q1
  06-Jul-24   11:09
  Dabur India expects mid to high digit revenue growth in Q1
  06-Jul-24   10:40
  Dhanlaxmi Bank gains as gross advances rises 6% YoY in Q1 FY25
  05-Jul-24   15:27
  HDFC Bank Ltd leads losers in 'A' group
  05-Jul-24   15:00
Back Top